載入中
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.
收盤時
US$23.52
−US$1.52 · -6.07%
盤後
US$23.1071
−US$0.4129 · -1.76%
10月13日 下午6:10 ET
盤中時間採用ET。市場資料可能有所延遲。
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.
日內區間
目前US$23.52
52週區間
目前US$23.52
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
14
估值過高
情緒
47
多空交錯
風險
45
風險偏高
動能
61
動能增強
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.
日內區間
目前US$23.52
52週區間
目前US$23.52
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1.26億 USD | 1.1億 USD | 1.75億 USD | 1.65億 USD | 2.75億 USD |
| 銷貨成本 | 1051.2萬 USD | 2.28億 USD | — | 2億 USD | 1.93億 USD |
| 毛利 | 1.15億 USD | −1.17億 USD | 1.75億 USD | −3498.4萬 USD | 8260.4萬 USD |
| 研究與開發 | 2.39億 USD | 2.28億 USD | 2.54億 USD | 2億 USD | 1.93億 USD |
| 銷售、一般及管理費用 | 6364.4萬 USD | 5888.6萬 USD | 5337.9萬 USD | 4748.9萬 USD | 3883.7萬 USD |
| 營業費用 | 2.93億 USD | 6121.5萬 USD | 3.07億 USD | 4748.9萬 USD | 3883.7萬 USD |
| 利息收入 | 2752.4萬 USD | 3193萬 USD | 1862.6萬 USD | 481.7萬 USD | 86.2萬 USD |
| 利息支出 | 3192.7萬 USD | 3664.3萬 USD | — | — | 1.3萬 USD |
| 折舊和攤銷 | 1051.2萬 USD | 1210.7萬 USD | 1149.8萬 USD | 879.9萬 USD | 749.1萬 USD |
| 營業利益 | −1.78億 USD | −1.78億 USD | −1.32億 USD | −8247.3萬 USD | 4376.7萬 USD |
| 淨利 | −9192.3萬 USD | −2.33億 USD | −1.33億 USD | −5518.1萬 USD | 8263.1萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$34.40
上漲空間 46.26%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI6391.7萬0.00%2.3兆 USD0.03%US$381.32-0.07%
iShares Russell 2000 ETFIWM4476.85萬0.06%787.4億 USD0.19%US$276.7-0.43%
State Street SPDR S&P Biotech ETFXBI3405.35萬0.33%103.03億 USD0.35%US$146.8-3.04%
Vanguard Extended Market ETFVXF2342.71萬0.02%954億 USD0.05%US$232.54-0.42%
iShares Russell 2000 Value ETFIWN1617.58萬0.12%137.49億 USD0.24%US$210.99-0.05%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM1558.99萬0.10%157.12億 USD0.03%US$53.49+0.13%
iShares Biotechnology ETFIBB1365.78萬0.13%108.2億 USD0.44%US$200.02-2.08%
Invesco S&P SmallCap Momentum ETFXSMO1127.79萬0.39%28.69億 USD0.35%US$81.03-0.34%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMiShares Biotechnology ETFIBBInvesco S&P SmallCap Momentum ETFXSMOAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
